CX-2051: Unlocking EpCAM as a Cancer Target via a Masked EPCAM-Directed Topo1 ADC
- EpCAM is highly and uniformly expressed in CRC, but its normal tissue expression has precluded targeting EpCAM with systemic therapies
- Introducing CX-2051 as a first-in-class masked EpCAM targeted Topo1 ADC with compelling preclinical profile and early Phase I data
- CX-2051 is being rapidly advanced in the clinic in CRC with a path to expanding to other EpCAM expressing solid tumours